How would you approach adjuvant therapy in a patient with HR+ breast cancer with a high RS (>25) given the current COVID-19 pandemic?  

The starting point for consideration of adjuvant chemotherapy is to quantify the risk of a distant recurrence. For estrogen receptor positive, HER2 negative breast cancer, Oncotype Dx RS data are critical for understanding the risk of a distant recurrence1 as well as endocrine and chemotherapy respo...

In the face of the COVID-19 pandemic and the increased mortality of elderly patients with COVID-19, the potential benefit of adjuvant chemotherapy in elderly individuals with ER pos HER2 neg needs to be carefully weighed against the potentially increased risk of complications. I think one could dela...